Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Adderall XR

This page shows the latest Adderall XR news and features for those working in and with pharma, biotech and healthcare.

Shire offloads oncology unit to Servier for $2.4bn

Shire offloads oncology unit to Servier for $2.4bn

The neuroscience arm includes Shire’s attention-deficit hyperactivity drugs such as Adderall XR (mixed amphetamine salts) and brought in $2.66bn in sales last year.

Latest news

  • Shire claims FDA approval for slow-cooked ADHD drug Shire claims FDA approval for slow-cooked ADHD drug

    modest $288m by 2020, mainly because of anticipated payer resistance in the US as the new drug has the same ingredients as Adderall XR. ... Either way the new drug is a boost to Shire's ADHD franchise now that Adderall XR and Intuniv (guanfacine) have

  • Shire pitching at adult ADHD product launch in 2017 Shire pitching at adult ADHD product launch in 2017

    Adults already receive treatment for ADHD off-label using drugs such as Adderall and Adderall XR - both also based on mixed amphetamine salts - but it is though that a sizeable proportion

  • Shire reaches $56.5m US marketing malpractice settlement Shire reaches $56.5m US marketing malpractice settlement

    Shire reaches $56.5m US marketing malpractice settlement. Justice Department agreement covers activities for drugs including Adderall. ... The allegations included its attention deficit disorder (ADHD) drugs Adderall XR and Vyvanse.

  • Pay-for-delay deals lead to inflated drug prices says study Pay-for-delay deals lead to inflated drug prices says study

    Pay-for-delay deals lead to inflated drug prices says study. Based on analysis of delayed market entry of generic Adderall XR in US. ... The study models a deal that delayed generic competition to Shire's attention-deficit hyperactivity disorder (ADHD)

  • Shire misses Q1 targets as Replagal sales fall Shire misses Q1 targets as Replagal sales fall

    Despite these setbacks, Shire's core attention-deficit hyperactivity disorder (ADHD) franchise delivered the goods, with Vyvanse (lisdexamfetamine) and Adderall XR (mixed amphetamine salts) doing better than expected. ... Vyvanse grew 15 per cent to

More from news
Approximately 3 fully matching, plus 76 partially matching documents found.

Latest appointments

  • Shire elects new chair Shire elects new chair

    During that time Shire has grown substantially, although has struggled in recent years with generic competition for big-selling attention deficit-hyperactivity disorder (ADHD) drug Adderall XR and plans to downsize

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Quick links

Infographics

Multimedia